Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2011

Open Access 01-04-2011 | Original Article

Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group

Authors: Andreas Gal, Derralynn A. Hughes, Bryan Winchester

Published in: Journal of Inherited Metabolic Disease | Issue 2/2011

Login to get access

Excerpt

Guidelines on diagnostics and therapy of Fabry disease have already been compiled in a number of European countries and are being prepared in others. A synthesis of these national guidelines seems to be a sensible option for preparing a prospective European consensus document in the not too distant future. While clinical diagnostics is extensively discussed in the various guidelines, at present there is no consensus on laboratory diagnostic tests for Fabry disease either at national level or at the level of the European Union. There is a widespread variation concerning the diagnostic value of the various methods, such as enzyme activity testing, gene analysis, biopsies, Gb3 measurement etc. and on what should be used and how they compare, if indeed they do. This results in lack of agreement regarding the clinical pathology of the condition. …
Literature
go back to reference Aerts JM, Groener JE, Kuiper S et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817PubMedCrossRef Aerts JM, Groener JE, Kuiper S et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817PubMedCrossRef
go back to reference Banikazemi M, Bultas J, Waldek S et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146:77–86PubMed Banikazemi M, Bultas J, Waldek S et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146:77–86PubMed
go back to reference Clark NE, Garman SC (2009) The 1.9 a structure of human alpha-N-acetylgalactosaminidase: the molecular basis of Schindler and Kanzaki diseases. J Mol Biol 393:435–447PubMedCrossRef Clark NE, Garman SC (2009) The 1.9 a structure of human alpha-N-acetylgalactosaminidase: the molecular basis of Schindler and Kanzaki diseases. J Mol Biol 393:435–447PubMedCrossRef
go back to reference Eng CM, Guffon N, Wilcox WR et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease. N Engl J Med 345:9–16PubMedCrossRef Eng CM, Guffon N, Wilcox WR et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease. N Engl J Med 345:9–16PubMedCrossRef
go back to reference Filoni C, Caciotti A, Carraresi L et al. (2008) Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients’ fibroblasts results in Fabry disease. Eur J Hum Genet 16:1311–1317PubMedCrossRef Filoni C, Caciotti A, Carraresi L et al. (2008) Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients’ fibroblasts results in Fabry disease. Eur J Hum Genet 16:1311–1317PubMedCrossRef
go back to reference Gal A (2010) Molecular genetics of Fabry disease and genotype–phenotype correlation. In Elstein et al. eds. Fabry disease. Springer Science + Business Media B.V. pp. 3-19 Gal A (2010) Molecular genetics of Fabry disease and genotype–phenotype correlation. In Elstein et al. eds. Fabry disease. Springer Science + Business Media B.V. pp. 3-19
go back to reference Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr 96(Suppl 455):6–16CrossRef Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr 96(Suppl 455):6–16CrossRef
go back to reference Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319–335PubMedCrossRef Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319–335PubMedCrossRef
go back to reference Gaspar P, Herrera J, Rodrigues D et al. (2010) Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet 11:19–26PubMedCrossRef Gaspar P, Herrera J, Rodrigues D et al. (2010) Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet 11:19–26PubMedCrossRef
go back to reference Hughes DA, Elliott PM, Shah J et al. (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 94:153–158PubMedCrossRef Hughes DA, Elliott PM, Shah J et al. (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 94:153–158PubMedCrossRef
go back to reference Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ (2002) Alternative splicing in the α-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 70:994–1002PubMedCrossRef Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ (2002) Alternative splicing in the α-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 70:994–1002PubMedCrossRef
go back to reference Lai LW, Whitehair O, Wu M-J, O’Meara M, Lien Y-H H (2003) Analysis of splice-site mutations of the α-galactosidase A gene in Fabry disease. Clin Genet 63:476–482PubMedCrossRef Lai LW, Whitehair O, Wu M-J, O’Meara M, Lien Y-H H (2003) Analysis of splice-site mutations of the α-galactosidase A gene in Fabry disease. Clin Genet 63:476–482PubMedCrossRef
go back to reference Li Y, Scott CR, Chamoles NA et al. (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785–1796PubMedCrossRef Li Y, Scott CR, Chamoles NA et al. (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785–1796PubMedCrossRef
go back to reference Lin HY, Ching KW, HSu JH et al. (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450–456PubMedCrossRef Lin HY, Ching KW, HSu JH et al. (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450–456PubMedCrossRef
go back to reference Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217–222 Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217–222
go back to reference Rombach SM, Dekker N, Bouwman MG et al. (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta May 13. [Epub ahead of print] PubMed PMID: 20471476 Rombach SM, Dekker N, Bouwman MG et al. (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta May 13. [Epub ahead of print] PubMed PMID: 20471476
go back to reference Schiffmann R, Kopp JB, Austin HA et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRef Schiffmann R, Kopp JB, Austin HA et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRef
go back to reference Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354PubMedCrossRef Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354PubMedCrossRef
go back to reference Sessa A, Meroni M, Battini G et al. (2003) Studio multicentrico Italiano sulla malattia di Anderson-Fabry. Evolution of renal pathology in Fabry disease. Acta Paediatr 92 (Suppl 443): 6-8; discussion 5. PubMed PMID: 14989458 Sessa A, Meroni M, Battini G et al. (2003) Studio multicentrico Italiano sulla malattia di Anderson-Fabry. Evolution of renal pathology in Fabry disease. Acta Paediatr 92 (Suppl 443): 6-8; discussion 5. PubMed PMID: 14989458
go back to reference Togawa T, Kodama T, Suzuki T et al. (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab Apr 1. [Epub ahead of print] PubMed PMID: 20409739 Togawa T, Kodama T, Suzuki T et al. (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab Apr 1. [Epub ahead of print] PubMed PMID: 20409739
go back to reference Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE (2006) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29:106–111PubMedCrossRef Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE (2006) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29:106–111PubMedCrossRef
go back to reference Vedder AC, Linthorst GE, van Breemen MJ et al. (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78PubMedCrossRef Vedder AC, Linthorst GE, van Breemen MJ et al. (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78PubMedCrossRef
go back to reference Whitfield PD, Calvin J, Hogg S et al. (2005) Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J Inherit Metab Dis 28:21–33PubMedCrossRef Whitfield PD, Calvin J, Hogg S et al. (2005) Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J Inherit Metab Dis 28:21–33PubMedCrossRef
go back to reference Winchester B, Young E (2010) Laboratory diagnosis of Fabry disease. In Elstein et al. eds. Fabry disease. Springer Science + Business Media B.V. pp. 111–132 Winchester B, Young E (2010) Laboratory diagnosis of Fabry disease. In Elstein et al. eds. Fabry disease. Springer Science + Business Media B.V. pp. 111–132
go back to reference Young E, Mills K, Morris P et al. (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr 94:51–54CrossRef Young E, Mills K, Morris P et al. (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr 94:51–54CrossRef
go back to reference Zhang XK, Elbin CS, Turecek F et al. (2010) Multiplex lysosomal enzyme activity assay on dried blood spots using tandem mass spectrometry. Methods in molecular biology 603:339–350PubMedCrossRef Zhang XK, Elbin CS, Turecek F et al. (2010) Multiplex lysosomal enzyme activity assay on dried blood spots using tandem mass spectrometry. Methods in molecular biology 603:339–350PubMedCrossRef
Metadata
Title
Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
Authors
Andreas Gal
Derralynn A. Hughes
Bryan Winchester
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2011
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9261-9

Other articles of this Issue 2/2011

Journal of Inherited Metabolic Disease 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.